[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369230-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369230-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","generation-of-frameshift-mutated-tgfr2-specific-t-cells-in-healthy-subjects-following-administration-with-cancer-vaccine-candidate-fmpv-1gm-csf-in-a-phase-1-study","Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study","","FMPV-1, an investigational cancer-specific vaccine component designed to activate T cell responses against transforming growth factor beta receptor 2 (TGFβR2) frameshift mutations, was evaluated in a first-in-human phase 1 study. Sixteen healthy male subjects received FMPV-1 plus GM-CSF injections on Days 1, 8, 15, 29 and 43 and were followed to Day 365. Delayed type hypersensitivity testing showed conversion from DTH-negative baseline to positivity in most subjects. Frameshift mutant TGFβR2-specific T cells persisted after 6 and 12 months, with limited mild injection-site adverse events and no clinically important changes in safety measures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/generation-of-frameshift-mutated-tgfr2-specific-t-cells-in-healthy-subjects-following-administration-with-cancer-vaccine-candidate-fmpv-1gm-csf-in-a-phase-1-study/369230/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/generation-of-frameshift-mutated-tgfr2-specific-t-cells-in-healthy-subjects-following-administration-with-cancer-vaccine-candidate-fmpv-1gm-csf-in-a-phase-1-study/369230.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of FMPV-1 in this phase 1 study?","Question",{"text":63,"@type":64},"FMPV-1 is designed to activate T cell responses targeting frameshift mutations in TGFβR2, aiming to generate cancer-specific immunity relevant to MSI-H cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was immunogenicity assessed in healthy subjects?",{"text":68,"@type":64},"Immunogenicity included a delayed type hypersensitivity (DTH) skin reactivity test and detection of FMPV-1/GM-CSF–induced frameshift mutant TGFβR2-specific T cells over follow-up.",{"name":70,"@type":61,"acceptedAnswer":71},"What safety findings were reported after vaccination with FMPV-1 plus GM-CSF?",{"text":72,"@type":64},"Adverse events were limited to mild injection site reactions. No evidence of related systemic signs and no clinically important changes in vital signs, ECG, or laboratory measures were observed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369230,1790708966,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Immunology, Immunotherapy (2025) 74:115 [https://doi.org/10.1007/s00262-025-03969-6](https://doi.org/10.1007/s00262-025-03969-6)  \nGeneration of frameshift‑mutated TGFβR2‑specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV‑1/GM‑CSF in a phase 1 study  \nElse Marit Inderberg1 · Nand Singh2 · Robert Miller3 · Sarah Arbe‑Barnes3 · Henrik K. Eriksen3 · Berit lversen4 · Hedvig Vidarsdotter Juul1 · Jon Amund Eriksen3 · Karianne Risberg Handeland4  \nReceived: 8 November 2024 / Accepted: 3 February 2025 / Published online: 25 February 2025 © The Author(s) 2025  \nAbstract  \nFMPV-1 is a component ofFMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer T cell responses targeting frameshift mutations of MSI-H cancers. FMPV-1 is designed to activate T cell responses against transforming growth factor β receptor 2 (TGFβR2) frameshift mutation. Microsatellite instability high (MSI-H) gastrointestinal cancers frequently harbour TGFβR2 frameshift mutations. This first-in-human, phase 1, single centre, open-label study included 16 healthy male subjects who received FMPV-1 (0.15 mg/injection) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) (0.03 mg/injection) as two separate, co-located, injections on Days 1, 8, 15, 29 and 43. All subjects were followed to Day 365. A FMPV-1-specific delayed type hypersensitivity (DTH) skin reactivity test was performed with FMPV-1 (without GM-CSF) on Days 1, 29 and 43 with assessment after 2 days. All subjects were DTH negative at baseline, 8/16 were positive on Day 31 and 15/16 were positive on Day 45. Furthermore, the FMPV-1/GM-CSF induced frameshift mutant TGFβR2-specific T cells after the short vaccination period, and specific T cells were still detectable after 6 and 12 months indicating induction of frameshift mutant TGFβR2-specific T memory cells. Adverse events were limited to mild injection site reactions with no evidence of related systemic signs or symptoms. No other clinically important changes to vital signs, electrocardiograms, haematological, coagulation or laboratory measures related to treatment were observed. FMPV-1/GM-CSF was well tolerated and generated vaccine-specific T cell immune responses in healthy subjects. These findings support clinical studies in patients with, or at risk of, cancers carrying TGFβR2 frameshift mutations.  \n[Clinical trial identification](Clinical trial identification: ClinicalTrials.gov: NCT05238558. EudraCT: 2020-004363-80)[: ClinicalTrials.gov: NCT05238558. EudraCT: 2020-004363-80](Clinical trial identification: ClinicalTrials.gov: NCT05238558. EudraCT: 2020-004363-80) .  \nKeywords Peptide vaccine · Immunotherapy · GM-CSF · TGFβR2 · Immune response · Lynch syndrome  \nAbbreviations  \nAE Adverse event  \ncfDNA Cell-free DNA  \ndMMR Deficiency in DNA mismatch repair  \nDTH Delayed type hypersensitivity  \nECG Electrocardiogram  \n* Sarah Arbe-Barnes [sarah.arbe-barnes@hubrobio.com](sarah.arbe-barnes@hubrobio.com)  \n1 Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University HospitalRadiumhospitalet, Oslo, Norway  \n2 Medical Department, Quotient Sciences, Nottingham, UK  \n3 Hubro BioScience AS, Oslo, Norway  \n4 Hubro Therapeutics AS, Oslo, Norway  \nGM-CSF  \nID  \nIU  \nMAPK  \nMSI-H  \nNE  \nPBMCs QTcF  \nSITGFβR2 ULN  \nGranulocyte-macrophage colony-stimulating factor  \nIntradermal  \nInternational units  \nMitogen-activated protein kinase Microsatellite instability high  \nNon-evaluable  \nPeripheral blood mononuclear cells Fridericia-corrected QT interval Stimulation Index  \nTransforming growth factor β receptor 2 Upper limit of normal  \nIntroduction  \nMicrosatellite instability high (MSI-H) occurs in various cancer types and in over 95% of patients with Lynch syndrome, or hereditary non-polyposis colorectal cancer where tumours may develop at a relatively young age [1] .  \nMSI-H/dMMR tumours characteristically involve frameshift mutat","cbCaiuVZcOdBKnXO","https://ap.wps.com/l/cbCaiuVZcOdBKnXO","pdf",3666480,"English","# Abstract\n## Study design and dosing\n## Immunogenicity outcomes (DTH and T-cell responses)\n## Safety and tolerability\n# Introduction\n## MSI-H and Lynch syndrome background\n## Neoantigens and rationale for vaccine-driven T-cell immunity\n## Role of FMPV-3 and GM-CSF as an adjuvant\n## FMPV-1 peptide design and biological context","[{\"question\":\"What is the purpose of FMPV-1 in this phase 1 study?\",\"answer\":\"FMPV-1 is designed to activate T cell responses targeting frameshift mutations in TGFβR2, aiming to generate cancer-specific immunity relevant to MSI-H cancers.\"},{\"question\":\"How was immunogenicity assessed in healthy subjects?\",\"answer\":\"Immunogenicity included a delayed type hypersensitivity (DTH) skin reactivity test and detection of FMPV-1/GM-CSF–induced frameshift mutant TGFβR2-specific T cells over follow-up.\"},{\"question\":\"What safety findings were reported after vaccination with FMPV-1 plus GM-CSF?\",\"answer\":\"Adverse events were limited to mild injection site reactions. No evidence of related systemic signs and no clinically important changes in vital signs, ECG, or laboratory measures were observed.\"}]","Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study | PDF",1790181520,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d823e4deb6e498a18a0f7109098bd49.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cc6a8bfbe51c453ba2dcd1dc13294fc.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bc2c5d4a9b90b7c2c77322313403276.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4720f781ec90a718bc8ec4a05b8e364.webp",980,1301]